Dr. Wu is currently serving as Chief Operating Officer of Clearbridge BioMedics, overseeing the company’s business, product and research development and general operations which include regulatory approvals for the Company’s products. He was previously General Manager for 3 years, with oversight of key operations and activities. Prior to his general management role, he was the Project Director, undertaking the incubation and commercialisation pathway for the ClearCell®product.
Previously, he served as the Technical Director of CordLife Group for over 3 years, and led a team of technologists from around the region for the management of laboratory and technical operations within CordlLife Group and its associates. Also leading the medical affairs team, Dr. Wu was involved in a series of firsts in cord blood applications in Singapore, such as cerebral palsy and neuroblastoma.
Prior to joining CordLife, Dr. Wu worked for A-Bio Pharma in process development. He holds a Bachelors and a PhD in Biochemical Engineering from University College, London.
20-22 APRIL 2017 | San Francisco, USA | Plenary SessionLearn More
NewsGenomeWeb Feature: John Wayne Cancer Institute and Clearbridge BioMedics announce partnership to develop CTC CoRE in the U.S. PR Newswire: John Wayne Cancer Institute, and Clearbridge BioMedics announce partnership to develop Circulating Tumor Cell Centre of Research Excellence in the U.S. BioSpectrum: John Wayne Cancer Institute and Clearbridge BioMedics announce partnership
20-22 APRIL 2017 | San Francisco, USA | Plenary SessionRead more